Safety and antitumor activity of dostarlimab in patients with advanced or recurrent DNA mismatch repair deficient/microsatellite instability-high (dMMR/MSI-H) or proficient/stable (MMRp/MSS) endometrial cancer: interim results from GARNET—a phase I, single-arm study

Autor: Lucy Gilbert, Ana Oaknin, Prafull Ghatage, Rebecca Kristeleit, Wei Guo, Sharad Ghamande, Valentina Boni, Jubilee Brown, Xinwei Han, Vanessa Samouëlian, Ellie Im, Renaud Sabatier, Anna V Tinker, David M O’malley, Bhavana Pothuri, Cara Mathews, Jennifer Veneris, Tao Duan, Linda Duska, Joshua Press, Charles Leath III, Sybil Zildjian

Publikováno v: Journal for ImmunoTherapy of Cancer, Vol 10, Iss 1 (2022)

Externí odkaz: https://doaj.org/article/e14cae0105ca4a77863badc972ff7d01

O012/#352 Atezolizumab and bevacizumab in recurrent endometrial cancer: a phase II, multi institutional trial

Autor: Katherine Fuh, Debra Richardson, Rebecca Arend, Carolyn Mccourt, Andrea Hagemann, Margaret Liang, Laura Holman, Christina Washington, Joan Walker, Robert Mannel, Grace Youn, David Mutch, Warner Huh, Andrew Cohoon, Charles Leath Iii, Matthew Powell, Camille Gunderson-Jackson, Kathleen Moore

Publikováno v: Oral Abstracts (Regular and Late-Breaking Submission).

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::b7fdf58037f86708d221a96b836d8fe2
https://doi.org/10.1136/ijgc-2022-igcs.14

TP043/#1565 Phase II activity trial of high dose radiation and chemosensitization in patients with macrometastatic lymph node spread after sentinel node biopsy in vulvar cancer: groningen international study on sentinel nodes in vulvar cancer III (GROINSS-V III/NRG-GY024)

Autor: Lilian Gien, Brian Slomovitz, Mario Leitao, Ate Gj Van Der Zee, Carien Creutzberg, An Kl Reyners, Petronella Witteveen, Diandra Ayala-Peacock, Jyoti Mayadev, Charles Leath Iii, Maaike Oonk

Publikováno v: E-Posters (Trials In Progress).

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::29b149a19427ab82cbc6c9aca00a61a4
https://doi.org/10.1136/ijgc-2022-igcs.552

TP022/#1424 A phase I/II study evaluating intraperitoneal GEN-1 in combination with neoadjuvant chemotherapy in patients newly diagnosed with advanced epithelial ovarian cancer

Autor: Premal Thaker, Debra Richardson, William Bradley, Lindsay Kuroki, Robert Holloway, Stephen Depasquale, Mark Reed, Amy Bregar, Jennifer Scalici, Melanie Bergman, Charles Leath Iii, Maria Bell, Christopher Darus, Karen Finkelstein, Bhavana Pothuri, David Warshal, Nicholas Borys

Publikováno v: E-Posters (Trials In Progress).

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::8113bf21338274f0ea51515a83733d83
https://doi.org/10.1136/ijgc-2022-igcs.531

Safety and antitumor activity of dostarlimab in patients with advanced or recurrent DNA mismatch repair deficient/microsatellite instability-high (dMMR/MSI-H) or proficient/stable (MMRp/MSS) endometrial cancer: interim results from GARNET—a phase I, single-arm study

Autor: Ana Oaknin, Lucy Gilbert, Anna V Tinker, Jubilee Brown, Cara Mathews, Joshua Press, Renaud Sabatier, David M O’Malley, Vanessa Samouelian, Valentina Boni, Linda Duska, Sharad Ghamande, Prafull Ghatage, Rebecca Kristeleit, Charles Leath III, Wei Guo, Ellie Im, Sybil Zildjian, Xinwei Han, Tao Duan, Jennifer Veneris, Bhavana Pothuri

Publikováno v: Journal for ImmunoTherapy of Cancer, Vol 10, Iss 1 (2022)
Scientia
Journal for Immunotherapy of Cancer
Journal for Immunotherapy of Cancer, 2022, 10 (1), pp.e003777. ⟨10.1136/jitc-2021-003777⟩

BackgroundDostarlimab is a humanized monoclonal antibody that binds with high affinity to PD-1, resulting in inhibition of binding to PD-L1 and PD-L2. We report interim data from patients with endometrial cancer (EC) participating in a phase I trial

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4d05449afa4e84daf1aeed6e17dd65d8
https://jitc.bmj.com/content/10/1/e003777.full